Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 12 results

      community Breezula Phase III 12-Month Data Released by Cosmo Pharma

       42 upvotes 5 months ago
      Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

      community Topical Dutasteride Experiment

       1 upvotes 2 months ago
      The user is experimenting with a homemade topical dutasteride formulation to reduce hair loss while minimizing systemic absorption, using MCT oil, almond oil, vitamin E, tea tree oil, and lavender oil. They are monitoring hair growth and side effects, particularly focusing on sexual health, and are open to feedback on their approach.

      community Minoxidil Sulfate makes everyone a responder

       258 upvotes 1 year ago
      Minoxidil sulfate is more effective than regular minoxidil, especially for those with low sulfotransferase levels or scalp sensitivity, but it is unstable unless delivered in a liposomal format. Combining minoxidil with tretinoin can enhance effectiveness, and stopping minoxidil use can lead to rapid hair loss.

      community DHT nearly doubled after switching to oral Fin

       5 upvotes 6 months ago
      The user switched from topical Minoxidil and Finasteride to oral Finasteride and reduced testosterone, expecting to lower DHT, but instead, DHT increased and hair loss worsened. The user is seeking advice on whether to return to the previous topical treatment or if others have experienced similar issues with oral Finasteride while on TRT.

      community My hair loss journey and routine.

      in Progress Pictures  1197 upvotes 1 year ago
      The user successfully managed hair loss using Finasteride, Minoxidil, Ketoconazole shampoo, and a hair mask, experiencing significant hair growth and improved density. They attribute their success to consistency, improved nutrition, and a dedicated routine.